OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
February 14 2017 - 12:00PM
OpGen, Inc. (NASDAQ:OPGN) today announced preliminary data
demonstrating the ability to rapidly and accurately predict
bacterial antibiotic susceptibility using resistance gene profiles.
The data were presented at the Advances in Genome Biology and
Technology (AGBT) meeting, which is taking place from February
13-16, 2017 in Hollywood Beach, FL. These preliminary results
support OpGen’s ongoing genomic and bioinformatics efforts to
complete development and commercialization of rapid and highly
accurate molecular antibiotic susceptibility determination products
for hospital- and network-wide infection prevention and patient
management.
“These data highlight the unique ability of our rapid testing
approach in development to considerably reduce the time necessary
to acquire predicted resistance results compared to traditional
antibiotic susceptibility tests (AST). The presented data suggest
this rapid testing approach predicts bacterial antibiotic
resistance using an algorithm based on minimum inhibitory
concentration values with the average positive predictive values
greater than 90% for six Gram-negative species commonly known to
harbor resistance genes (E. coli, E. cloacae, E. aerogenes, A.
baumannii, K. pneumoniae and P.aeruginosa). By identifying and
using accurate gene profiles, we anticipate that actionable results
can be generated within hours instead of days,” said Evan Jones,
Chairman and CEO of OpGen.
The poster titled: “Development of a Rapid Molecular Antibiotic
Susceptibility Test,” was presented by Terry Walker, Ph.D., Senior
Vice President of Research & Development. Key findings from the
presentation include:
- Combined experimental results were used to develop statistical
models for predicting phenotypic resistance for several antibiotics
based on detection of resistance for several antibiotics based on
detection of resistance genes.
- Genotypic algorithms predicted phenotypic resistance with
average positive predictive values ranging from 92% to 97%.
- Average sensitivities for each species ranged from 78% to 98%
while average specificity ranged from 74% to 91%.
“These preliminary results illustrate our ability to develop
algorithms that can leverage resistance gene profiles to predict
phenotypic resistance accurately,” said Dr. Walker. “These initial
data are very encouraging. We anticipate further improvements in
test performance as we complete our planned genomic and phenotypic
testing of approximately 10,000 multi-drug resistant organisms in
the coming months.”
About OpGen OpGen, Inc. is harnessing
the power of informatics and genomic analysis to provide complete
solutions for patient, hospital and network-wide infection
prevention and treatment. Learn more at www.opgen.com and
follow OpGen on Twitter and LinkedIn.
Forward-Looking StatementsThis press release
includes statements relating to the company's rapid testing
product in development. These statements and other statements
regarding our future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control, and which
may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those
described include, but are not limited to, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory approval for and commercialize our mAST™ product in
development, the rate of adoption of our products and services by
hospitals and other healthcare providers, and other economic and
competitive factors. For a discussion of the most significant risks
and uncertainties associated with OpGen's business, please review
our filings with the Securities and Exchange Commission (SEC). You
are cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
OpGen Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-591-3443
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024